ReviewEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2021
Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy.
Review in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Assessment of Supplementation with Different Biomolecules in the Prevention and Treatment of COVID-19.Nutrients · 2024Review
- Review
- Endoplasmic Reticulum Stress in Elderly Patients with COVID-19: Potential of Melatonin Treatment.Viruses · 2023Review
- Chronobiological Efficacy of Combined Therapy of Pelargonium Sidoides and Melatonin in Acute and Persistent Cases of COVID-19: A Hypothetical Approach.Advances in experimental medicine and biology · 2023Review
- Melatonin effect on platelets and coagulation: Implications for a prophylactic indication in COVID-19.Life sciences · 2022Review
- The CSHQ-DE Questionnaire Uncovers Relevant Sleep Disorders in Children and Adolescents with Long COVID.Children (Basel, Switzerland) · 2022Article
- Modified Release of the Pineal Hormone Melatonin from Matrix Tablets Containing Poly(Polymers · 2022Article
- Role of melatonin in respiratory diseases (Review).Experimental and therapeutic medicine · 2022Review
- Low-Molecular-Weight Synthetic Antioxidants: Classification, Pharmacological Profile, Effectiveness and Trends.Antioxidants (Basel, Switzerland) · 2022Review
- Melatonin biosynthesis pathways in nature and its production in engineered microorganisms.Synthetic and systems biotechnology · 2022Review
- Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection.Cellular and molecular life sciences : CMLS · 2022Review
- "LONG COVID"-A hypothesis for understanding the biological basis and pharmacological treatment strategy.Pharmacology research & perspectives · 2022Review
- A Peek into Pandora's Box: COVID-19 and Neurodegeneration.Brain sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo discuss the use of melatonin as an early treatment option on the first day of diagnosis for COVID-19.
methodsMedical Subject Headings terms "COVID-19" and "viral diseases" were manually searched on PubMed, and relevant articles were included.
resultsThe results showed that melatonin acts to reduce reactive oxygen species-mediated damage, cytokine-induced inflammation, and lymphopenia in viral diseases similar to COVID-19.
conclusionThese conclusions provide evidence for potential benefits in melatonin use for COVID-19 treatment as early as the day of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.